Abstract
Micrologix and Fujisawa are developing a gel formulation of MBI-226 for the potential treatment and prevention of various infections caused by both antibiotic-resistant and -sensitive bacteria. In September 2000, a phase III trial of MBI-226 for the potential prevention of catheter-related bloodstream infections was initiated.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 999-1003 |
| Number of pages | 5 |
| Journal | Current Opinion in Investigational Drugs |
| Volume | 4 |
| Issue number | 8 |
| State | Published - Aug 1 2003 |